FDA News Update

FDA QMSR Is Now in Effect: What Medical Device Companies Should Do Next

If you are a medical device company and you are still preparing for FDA inspections using the old Quality System Inspection Technique guide — stop….

Read More

Flavored E-Cigarette PMTAs in 2026: What FDA’s New Draft Guidance Actually Changes

The FDA’s Center for Tobacco Products issued a new draft guidance on March 9, 2026, that is the most detailed statement yet on how the…

Read More

FDA General Wellness Guidance 2026: What Wearable and Digital Health Companies Can and Can’t Do Now

If you’re building a wearable, wellness app, smart ring, recovery tracker, or connected health platform, FDA just updated the playbook — and the changes matter….

Read More

Will the FDA Eliminate Self-Affirmed GRAS? What the Proposed Rule Could Mean

The conversation around self-affirmed GRAS is evolving quickly, with lawmakers and regulators signaling potential changes that could reshape how food ingredients are evaluated and brought…

Read More

FDA GRAS Reform in 2026: What Food and Ingredient Companies Need to Know

The landscape of food ingredient safety is entering a period of significant transition in 2026. For decades, the “Generally Recognized as Safe” (GRAS) pathway has…

Read More

The FDA’s Quality Management System Regulation (QMSR): What the New Inspection Framework Means for Medical Device Companies

The medical device industry is currently navigating one of its most significant regulatory shifts in decades. For nearly thirty years, the Food and Drug Administration…

Read More

The FDA’s New Approach to “No Artificial Colors” Claims: Compliance Risks and Legal Considerations

The U.S. Food and Drug Administration has announced a new enforcement approach to products labeled “no artificial colors,” signaling heightened scrutiny for food and beverage…

Read More

503A vs 503B Compounding Pharmacies: Compliance Risks That Can Pull Products from the Market

Compounding pharmacies play a critical role in patient care, especially when commercially available drugs cannot meet specific clinical needs. However, the regulatory distinction between traditional…

Read More

Congress Targets the GRAS Process: Four Bills That Could Fundamentally Change FDA Food Ingredient Oversight

GRAS Loophole For more than two decades, the FDA’s “generally recognized as safe” (GRAS) framework has allowed food ingredients to enter the U.S. market either…

Read More

Importing Dietary Supplements into the U.S. in 2025: FDA, USDA, and Customs Pitfalls

The U.S. market for dietary supplements continues to expand in 2025, with global manufacturers eager to meet consumer demand for vitamins, minerals, and herbal products….

Read More

What the Shutdown-Ending Bill Means for Hemp, CBD, and Cannabinoid Products

The Hemp Provision in H.R. 5371: What the Shutdown-Ending Bill Means for Hemp, CBD, and Cannabinoid Products Congress quietly enacted one of the most sweeping…

Read More

The FDA’s Latest Warning Letters: What They Reveal About Cosmetic and Supplement Claims

In recent months, the U.S. Food and Drug Administration (FDA) has issued a series of warning letters that highlight recurring problems in how cosmetic and…

Read More